


## Functional Selectivity at GPCRs: New Opportunities in Psychiatric Drug Discovery

The superfamily of G-protein coupled receptors (GPCRs) is one of the largest gene families in the mammalian genome. GPCRs represent >50% of all current drug targets for treating numerous diseases that affect both peripheral and central nervous systems. Identification of novel GPCR drug targets and their promise for treatment in psychiatric disease has been recently slowed by the dearth of selective targets and changes in the pharmaceutical landscape. However, several recent advances in GPCR crystallization and *in vivo* pharmacology offer potentially exciting opportunities for therapeutics that target GPCRs in unique ways to treat psychiatric diseases (Kenakin and Christopoulos, 2013).

Current mathematical and pharmacological data support the conclusion that GPCRs are pluridimensional proteins that occupy numerous structural conformations and signaling states. Depending on the ligand, the GPCR has the ability to engage a G-protein and arrestin state, or favor one over the other (Figure 1). These conformations are determined by the type of ligand, the receptor type, as well as interacting accessory proteins. This concept termed ‘functional selectivity’ (also called, biased signaling, ligand-directed signaling) is the ability of a ligand to direct a GPCR toward a conformation that selectively evokes a particular stimulus–response and is now a well-accepted concept in the field of GPCR research. Some GPCR classes that have been studied in the context of functional selectivity *in vitro* and *in vivo* include: serotonin, opioid, adrenergic, cannabinoid, muscarinic, and metabotropic glutamate receptors (Luttrell and Gesty-Palmer, 2010).

A recent and elegant development in this field has the potential to greatly advance our understanding of functional selectivity and to open new doors for drug discovery. The study



**Figure 1.** Schematic of functional selectivity at GPCRs. Cartoon model depicting various states of functional selectivity. Depending on the ligand and the induced receptor conformation, GPCRs are capable of signaling through the G-protein-mediated signaling pathway or the arrestin-mediated signaling pathway independently or simultaneously. Wacker *et al* (2013) crystallized for the first time, both the G-protein and arrestin state of serotonin receptor. Similarly, ligands can be antagonists for both pathways, or only one pathway while agonizing the other (collateral agonists). This structure-based signaling complexity is thought to give rise to multiple different downstream outputs, and may involve additional, currently uncharacterized effectors. As we increase our understanding of the molecular architecture of these signaling states, the development of novel psychiatric treatments that target these states will become increasingly more possible.

uncovered a ‘snapshot’ of the serotonin 5HT<sub>2B</sub> receptor bound to ergotamine, an arrestin-biased ligand at this receptor (Wacker *et al*, 2013). For the first time, this paper and its complementary study, elucidated the molecular signature of the G-protein *vs* arrestin-biased conformation at serotonin receptors using an X-ray crystallography approach. Together, these reports suggest that for a GPCR to occupy an arrestin-biased (alternate-agonist) state, the ligand-receptor conformation sits in an intermediate state that includes both active and inactivate components, yet also interferes with G-protein signaling.

While the authors show convincing modeling for other GPCR types, whether this is indeed case for other biased ligands of other classes of GPCRs remains to be explored. However, this exciting result has the potential to accelerate our understanding of GPCR structure–function relationships, particularly as new ligands are developed for the treatment of psychiatric diseases. Having a clearer

understanding of how various ligand types interact with and stabilize GPCR conformations will provide chemists with the necessary tools to rationally design more selective compounds with better delivery, higher affinity, and fewer unwanted side effects.

Complimentary to these exciting molecular advances, contemporary reports have shown promising *in vivo* data indicating that functionally selective ligands may offer novel strategies to achieve pain relief without the traditional abuse liability, dysphorigenic properties, or psychomimetic components of traditional opioid receptor ligands (Bruchas and Chavkin, 2010; Bruchas *et al*, 2011) by selectively targeting G-protein *vs* arrestin-biased signaling states. Furthermore, advances in dopamine and serotonin receptor behavioral pharmacology have revealed that engaging D2R arrestin-biased signaling to GSK3 $\beta$  or 5HT<sub>2A</sub> arrestin-biased Src/Akt signaling may offer selective treatments for schizophrenia, psychosis, and other mood disorders (Schmid and Bohn,

2010; Urs *et al*, 2012). The combined efforts of molecular pharmacologists, biochemists, and behavioral pharmacologists to decipher these complex relationships between the molecular signatures of GPCRs and how various GPCR conformations ultimately transduce cellular responses into behavioral output are an active area of study for both Academia and Industry. These new discoveries are likely to provide novel therapeutic strategies for treating psychiatric diseases.

## ACKNOWLEDGEMENTS

This work was supported by NIH/NIDA: R01DA033396, R00DA025182, R21DA035144 (to MRB), and T32DA007261 (SDC).

Steven D Chang<sup>1,2,3</sup> and Michael R Bruchas<sup>1,2</sup>

<sup>1</sup>Department of Anesthesiology, Washington University, St Louis, MO, USA; <sup>2</sup>Department of Neurobiology, Washington University, St Louis, MO, USA; <sup>3</sup>Department of Psychiatry, Washington University, St Louis, MO, USA  
E-mail: bruchasm@wustl.edu

## FUNDING AND DISCLOSURE

The authors have no conflicts of interest or consulting relationships to disclose.

Bruchas MR, Chavkin C (2010). Kinase cascades and ligand-directed signaling at the kappa opioid receptor. *Psychopharmacology (Berl)* **210**: 137–147.

Bruchas MR, Schindler AG, Shankar H, Messinger DI, Miyatake M, Land BB *et al* (2011). Selective p38 $\alpha$  MAPK deletion in serotonergic neurons produces stress resilience in models of depression and addiction. *Neuron* **71**: 498–511.

Kenakin T, Christopoulos A (2013). Signalling bias in new drug discovery: detection, quantification and therapeutic impact. *Nat Rev Drug Discov* **12**: 205–216.

Luttrell LM, Gesty-Palmer D (2010). Beyond desensitization: physiological relevance of arrestin-dependent signaling. *Pharmacol Rev* **62**: 305–330.

Schmid CL, Bohn LM (2010). Serotonin, but not N-methyltryptamines, activates the serotonin 2A receptor via a  $\beta$ -arrestin2/Src/Akt signaling complex in vivo. *J Neurosci* **30**: 13513–13524.

Urs NM, Snyder JC, Jacobsen JPR, Peterson SM, Caron MG (2012). Deletion of GSK3 $\beta$  in D2R-expressing neurons reveals distinct roles for  $\beta$ -arrestin signaling in antipsychotic and lithium action. *Proc Natl Acad Sci USA* **109**: 20732–20737.

Wacker D, Wang C, Katritch V, Han GW, Huang X-P, Vardy E *et al* (2013). Structural features for functional selectivity at serotonin receptors. *Science* **340**: 615–619.


## Obesity, Food, and Addiction: Emerging Neuroscience and Clinical and Public Health Implications

Obesity is considered among the top three leading causes of preventable death and illness in the United States (Danaei *et al*, 2009). In the United States and elsewhere, obesity's prevalence has risen considerably since the 1980s, with one-third of US adults now obese (<http://www.win.niddk.nih.gov/statistics/>). How health care approaches obesity is changing, with the American Medical Association recently defining obesity as a disease (<http://www.bostonglobe.com/editorials/2013/06/28/ama-obesity-declaration-makes-third-america-ill/02nZ0a90RtKE3hOWy59KK/story.html>). Although the reasons why rates have risen are not entirely known and remain debated, the individual and societal costs necessitate an improved understanding. In this context, examining food and eating behaviors from interdisciplinary perspectives seems important in addressing an obesity epidemic.

Historically, obesity has been viewed from a metabolic perspective, with a

focus on energy balance (Ziauddeen *et al*, 2012). More recently, it has been questioned whether obesity might be conceptualized within an addiction framework and whether certain foods may be addictive (Gearhardt *et al*, 2011a). Over time, a motivating factor for food consumption has shifted from sustenance and energy balance to pleasurable/hedonic purposes. Thus, motivational factors (positive-reinforcement-related anticipatory pleasure or negative-reinforcement-related stress reduction) might link to obesity similarly as in drug addictions. Additionally, metabolic factors implicated in homeostatic regulation may relate differently to these constructs in obese as compared with lean individuals.

To examine directly, we studied 25 obese and 25 matched lean individuals using a guided-imagery fMRI task that included individualized cues relating to personal stressors, favorite foods, or neutral-relaxing situations (Jastreboff *et al*, 2013). Obese as compared with lean individuals showed increased activation in cortico-striato-limbic structures (striatum, insula, inferior frontal gyrus and amygdala) to favorite-food cues, and activations of thalamus and striatum correlated with subjective craving in obese but not lean individuals. Similarly, stress-related



**Figure 1.** Overlaps in the relationships in obese individuals between brain activations and insulin resistance (HOMA-IR) and brain activations and food craving. During favorite-food cue exposure, individuals with obesity show thalamic activations that correlate both with HOMA-IR and food craving (left, green color). During stress cue exposure, individuals with obesity show insular and striatal (in putamen) activations that correlate both with HOMA-IR and food craving (right, orange color). Brain slices are located at Talaraich levels of  $z = 6$  (left) and  $z = 4$  (right), respectively. Right side of the brain is displayed on the left. Additional details of the original research can be found in Jastreboff *et al* (2013).